| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 161 | STABILISED PROTEIN COMPOSITIONS BASED ON SEMIFLUORINATED ALKANES | EP13700911.4 | 2013-01-22 | EP2806886A1 | 2014-12-03 | GÜNTHER, Bernhard; THEISINGER, Bastian; THEISINGER, Sonja; SCHERER, Dieter; WILSON, Clive; PETTIGREW, Anthony; HÜTTIG, Annette |
| The invention provides novel compositions of bioactive polypeptides and proteins with improved stability and shelf-life. The compositions are based on liquid vehicles selected from semifluorinated alkanes. These vehicles are remarkably effective in protecting polypeptides and proteins from degradation and/or aggregation. The compositions are useful for topical administration, e.g. into an eye, or by parenteral injection, e.g. via the subcutaneous or intramuscular route. | ||||||
| 162 | A NOVEL PHARMACEUTICAL PREPARATION FOR PREECLAMPSIA, ECLAMPSIA, AND TOXEMIA AND THEIR RELATED SYMPTOMS AND RELATED DISORDERS OF PREGNANCY | EP09719395 | 2009-03-13 | EP2257305A4 | 2013-04-03 | FALLON JOAN M |
| A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the maternal GI tract to determine the likelihood of developing preeclampsia, pregnancy induced hypertension, and eclampsia/toxemia is disclosed. | ||||||
| 163 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF STAPHYLOCOCCUS AUREUS INFECTIONS AND FOR THE ERADICATION OR REDUCTION OF STAPHYLOCOCCUS AUREUS ON SURFACES | EP10729462 | 2010-01-06 | EP2373791A4 | 2012-05-23 | FALLON JOAN M; HEIL MATTHEW; FALLON JAMES J |
| 164 | CONTROLLED RELEASE OF BIOLOGICAL ENTITIES | EP05818407 | 2005-12-20 | EP1838289A4 | 2011-12-14 | FINNIE KIM SUZANNE; JACQUES DAVID; BARBE CHRISTOPHE JEAN ALEXANDRE; KONG LINGGEN |
| A process is provided for releasably encapsulating a biological entity. The process comprise combining a solution of a surfactant in a non-polar solvent with a precursor material and the biological entity to form an emulsion. The emulsion comprises a polar phase dispersed in a non-polar phase, wherein the polar phase comprises the biological entity. The particles comprising the biological entity are then formed from the polar phase. | ||||||
| 165 | PROCESS FOR PREPARING HYPOALLERGENIC AND NON-ALLERGENIC PEANUTS (ARACHIS HYPOGAEA) UTILIZING AN ENDOPEPTIDASE | EP08756724.4 | 2008-06-05 | EP2170106A1 | 2010-04-07 | AHMEDNA, Mohamed; YU, Jianmei; GOKTEPE, Ipek |
| The present invention relates to the use of a solution containing at least one endopeptidase to substantially reduce or completely eliminate allergenic proteins contained in the peanut (Arachis hypogea). In particular, the direct application of a solution containing at least one endopeptidase to either raw, blanched, or roasted peanuts or peanut products or derivates, has been shown to substantially reduce or completely eliminate the activity of allergenic proteins. The treated peanuts showed no degradation in quality or sensory acceptability, and have the flavor and aroma of natural whole peanuts. Hypoallergenic or non-allergenic peanuts produced in accordance with the present invention may be used as ingredients in various food products and other edible materials. | ||||||
| 166 | SERUM-FREE STABLE TRANSFECTION AND PRODUCTION OF RECOMBINANT HUMAN PROTEINS IN HUMAN CELL LINES | EP06777525.4 | 2006-06-29 | EP1896590A2 | 2008-03-12 | DING, Haiyan; WEGMANN, Cathleen; SCHRÖDER, Carola |
| The present invention relates to an improved method for the serum-free production of recombinant human proteins, in particular blood proteins, utilizing specific cell lines stably transfected under serum-free conditions with a specific vector carrying the gene coding for the protein of interest. Furthermore the invention relates to a production cell line stably transfected with said vector under serum-free conditions, a method for producing said production cell line, and the vector carrying the gene of interest itself. | ||||||
| 167 | CONTROLLED RELEASE OF BIOLOGICAL ENTITIES | EP05818407.8 | 2005-12-20 | EP1838289A1 | 2007-10-03 | FINNIE, Kim, Suzanne; JACQUES, David; BARBE, Christophe, Jean, Alexandre; KONG, Linggen |
| A process is provided for releasably encapsulating a biological entity. The process comprise combining a solution of a surfactant in a non-polar solvent with a precursor material and the biological entity to form an emulsion. The emulsion comprises a polar phase dispersed in a non- polar phase, wherein the polar phase comprises the biological entity. The particles comprising the biological entity are then formed from the polar phase. | ||||||
| 168 | Serum-free stable transfection and production of recombinant human proteins in human cell lines | EP05105965.7 | 2005-06-30 | EP1739179A1 | 2007-01-03 | Schröder, Carola; Wegmann, Cathleen; Ding, Haiyan |
The present invention relates to an improved method for the serum-free production of recombinant human proteins, in particular blood proteins, utilizing specific cell lines stably transfected under serum-free conditions with a specific vector carrying the gene coding for the protein of interest. Furthermore the invention relates to a production cell line stably transfected with said vector under serum-free conditions, a method for producing said production cell line, and the vector carrying the gene of interest itself. |
||||||
| 169 | Milk protein hydrolysates | EP94810352.8 | 1994-06-14 | EP0629350A1 | 1994-12-21 | Belli, Dominique C.A.; Eigenmann, Philippe; Kahn, Jean-Maurice; Polla, Barbara |
The use of cow's milk protein hydrolysate substantially free of allergenic proteins to induce cow's milk protein tolerance in children susceptible to cow's milk allergy and in the prophylaxis or treatment of type 1 diabetes mellitus in children susceptible to such disease. |
||||||
| 170 | Therapeutic selenium compositions and the use thereof | EP78300225.6 | 1978-08-01 | EP0000670A1 | 1979-02-07 | Levitt, Joseph R. |
Therapeutic compositions comprising certain selenium-containing compounds which exhibit therapeutic benefits in mammal hosts including humans are disclosed. The selenium compounds in accordance with this invention are preferably water soluble organic or inorganic compounds containing selenium such as alkali metal selenites and selenates. Among the therapeutic benefits exhibited by these compositions are the reduction in severity of, and improvements in recovery from, physically induced damage to body tissue which includes damage caused by surgical incisions, lacerations and burns. |
||||||
| 171 | 효소 전달 시스템, 및 제조 및 사용 방법 | KR1020187023838 | 2010-04-13 | KR1020180097762A | 2018-08-31 | |
| 본발명은코팅된소화효소제제, 및이러한제제를포함하는효소전달시스템및 제약조성물에관한것이다. 본발명은추가로, ADD, ADHD, 자폐증, 낭성섬유증및 다른행동및 신경계장애가있는사람을치료하기위한상기시스템, 제약조성물및 제제의사용및 제조방법에관한것이다. | ||||||
| 172 | 스타필로코쿠스 아우레우스 감염의 치료 또는 예방 및 표면 상의 스타필로코쿠스 아우레우스의 박멸 또는 감소를 위한 조성물 및 방법 | KR1020177000180 | 2010-01-06 | KR1020170005192A | 2017-01-11 | 팔론,조안엠.; 하일,매튜; 팔론,제임스제이. |
| 에스. 아우레우스감염을치료또는예방하기위한조성물및 방법이제공된다. 이러한조성물은제약조성물로서또는소독제, 위생제, 세제또는방부제로서제제화될수 있고, 에스. 아우레우스집단을박멸또는감소시킴으로써에스. 아우레우스에의한감염을치료또는예방하는데사용될수 있다. 이러한조성물은하나이상의소화효소, 예를들어, 하나이상의프로테아제, 리파제및 아밀라제를포함한다. 이러한조성물의사용방법이또한제공된다. | ||||||
| 173 | 감각 개선제 | KR1020137020954 | 2012-01-13 | KR1020140041427A | 2014-04-04 | 가토켄; 우에다노리코; 우에노히로시; 오노유코; 나카하타노리미치; 모리야다카히로; 고바야시다이사쿠 |
| 안전하고, 일상적으로 섭취 혹은 피부에의 도포에 의해, 말초에서의 감각의 둔화를 개선하는 효과를 나타내는 감각 개선제를 제공하는 것을 과제로 한다. 또, 본 발명은, 경구 섭취나 피부에의 도포에 의해 말초에서의 감각의 둔화를 개선하는 효과를 나타내는 감각 개선용 음식품 또는 사료, 화장품을 제공하는 것을 과제로 한다. 젖 유래 염기성 단백질 분획 혹은 젖 유래 염기성 단백질 분획 분해물을 유효 성분으로서 사용한 감각 개선제를 제공한다. 젖 유래 염기성 단백질 분획 혹은 젖 유래 염기성 단백질 분획 분해물을 경구 섭취, 혹은 피부에 직접 도포함으로써, 감각, 특히 말초에서의 감각의 둔화를 개선할 수 있어, 감각 개선용 음식품 또는 사료, 화장품으로 할 수 있다. | ||||||
| 174 | 인간 세포주에서 재조합 인간 단백질의 무혈청의 안정한형질감염 및 생산 | KR1020077030563 | 2006-06-29 | KR101320489B1 | 2013-10-30 | 슈뢰더카롤라; 베그만카틀린; 딩하이얜 |
| 본 발명은 목적 단백질(protein of interest)을 코딩하는 유전자를 운반하는 특정한 벡터에 의해 무혈청 조건에서 안정적으로 형질감염(transfect)된 불멸화된(immortalized) 인간 세포주의 개선된 무혈청 생산방법에 관한 것이다. 또한, 본 발명은 상기 방법에 의해 수득된 세포주의 생산, 상기 생산 세포주를 이용한 상기 목적 단백질의 생산 방법, 및 목적 유전자를 운반하는 특정한 벡터에 관한 것이다. 불멸화된 세포주, 무혈청 형질감염, 무혈청 생산방법 | ||||||
| 175 | 홍합 가수분해물을 유효성분으로 함유하는 항산화제 조성물 | KR1020100110606 | 2010-11-08 | KR1020120049042A | 2012-05-16 | 박표잠; 양현필; 오현정; 김은경 |
| PURPOSE: An anti-oxidative agent composition which includes mussel hydrolysate is provide to prevent and treat all kinds of diseases and aging which can be caused by active oxygen. CONSTITUTION: An anti-oxidative agent composition includes peptide which is separated from hydrolysate of mussel proteins as an active ingredient. The mussel protein hydrolysate is manufactured by the falling stages: dissolving lyophilized mussels in buffering solution; performing hydrolysis by adding protease in the solution; heating the hydrolysate in hot water; and filtering, concentrating, and drying the heated hydrolysate. The buffer solution is phosphate buffer or glycine-HCl buffer. | ||||||
| 176 | 스타필로코쿠스 아우레우스 감염의 치료 또는 예방 및 표면 상의 스타필로코쿠스 아우레우스의 박멸 또는 감소를 위한 조성물 및 방법 | KR1020117018327 | 2010-01-06 | KR1020110127140A | 2011-11-24 | 팔론,조안엠.; 하일,매튜; 팔론,제임스제이. |
| 에스. 아우레우스 감염을 치료 또는 예방하기 위한 조성물 및 방법이 제공된다. 이러한 조성물은 제약 조성물로서 또는 소독제, 위생제, 세제 또는 방부제로서 제제화될 수 있고, 에스. 아우레우스 집단을 박멸 또는 감소시킴으로써 에스. 아우레우스에 의한 감염을 치료 또는 예방하는데 사용될 수 있다. 이러한 조성물은 하나 이상의 소화 효소, 예를 들어, 하나 이상의 프로테아제, 리파제 및 아밀라제를 포함한다. 이러한 조성물의 사용 방법이 또한 제공된다. | ||||||
| 177 | 생물학적 존재의 제어된 방출 | KR1020077016764 | 2005-12-20 | KR1020070104563A | 2007-10-26 | 핀니킴수잔; 자크데이비드; 바비크리스토프진알렉산드르; 공링겐 |
| A process is provided for releasably encapsulating a biological entity. The process comprise combining a solution of a surfactant in a non-polar solvent with a precursor material and the biological entity to form an emulsion. The emulsion comprises a polar phase dispersed in a non-polar phase, wherein the polar phase comprises the biological entity. The particles comprising the biological entity are then formed from the polar phase. | ||||||
| 178 | METHOD FOR DIAGNOSING AND TREATING DYSAUTONOMIA AND OTHER DYSAUTONOMIC CONDITIONS | US16358979 | 2019-03-20 | US20190209667A1 | 2019-07-11 | Joan M. Fallon |
| A method for treating a Parkinson's patient with digestive/pancreatic enzymes involves administering an effective amount of digestive/pancreatic enzymes to an individual having the disorder in order to improve a symptom of the disorder. In addition, a method is provided for determining whether an individual has, or may develop, Parkinson's disease or related dysautonomic disorders and for determining whether an individual will benefit from the administration of pancreatic/digestive enzymes to treat the dysautonomic disorder. | ||||||
| 179 | Zwitterionic polymer bioconjugates and related methods | US14526846 | 2014-10-29 | US10130716B2 | 2018-11-20 | Shaoyi Jiang; Andrew Keefe; Hong Xue |
| Zwitterionic polymer and mixed charge copolymer bioconjugates, methods for making and using the bioconjugates. | ||||||
| 180 | Methods and Compositions for the Treatment of Symptoms of Prion Diseases | US15593129 | 2017-05-11 | US20180078623A1 | 2018-03-22 | Joan M. Fallon |
| A therapeutic composition for the treatment of the symptoms of prion diseases and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of a prion disease, or the likelihood of an individual to develop a prion disease is disclosed. | ||||||
QQ群二维码
意见反馈
意见反馈